References
- Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry34(6), 242–250 (2001).
- Reinstein MJ, Sonnenberg JG, Hedberg TG, Jones LE and Reyngold P. Oxcarbazepine versus divalproex sodium for the continuing treatment of mania. Clin. Drug Invest.23(10), 671–677 (2003).
- Vieta E. The role of third-generation anticonvulsants in the treatment of bipolar disorders. Clin. Neuropsychiatry1, 159–164 (2004).
- White HS. Mechanism of action of newer anticonvulsants. J. Clin. Psychiatry64(S8), 5–8 (2003).
- Schmidt D, Elger CE. What is the evidence that oxcarbamazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav.5, 627–635 (2004).
- Navarro C, Morales R, Cañabate A. Perfil terapéutico de los nuevos antiepilepticos. Rev. Psiquiatría Fac. Med. Barna.29(3), 177–180 (2002).
- Mueller AA, Stoll KD. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: studies in Germany. In: Anticonvulsats in Affective Disorders. Int. Cong. Series No 626. Emrich HM, Okuma T, Muller AA (Eds). Excerpta Medica, Amsterdam, The Netherlands 139–147 (1984).
- Emrich HM, Dose M, Von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorder. In: Anticonvulsants in Affective Disorders. Emrich HM, Okuma T, Mueller AA (Eds), Elsevier Science Publishers BV, Amsterdam, The Netherlands (1984).
- Emrich HM, Altmann H, Dose M, Von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol. Biochem. Behav.19(2), 369–372 (1983).
- Wagner KD, Kowatch RA, Emslie GJ et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am. J. Psychiatry163(7), 1179–1186 (2006).
- Leibenluft E. Editorial: Flying almost blind. Am. J. Psychiatry163(7), 1129–1131 (2006).
- Emrich HM. Studies with oxcarbazepine (trileptal) in acute mania. Int. Clin. Psychopharmacol.5, 83–88 (1990).
- Emrich HM, Dose M, von Zersson D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J. Affect. Disord.8(3), 243–250 (1985).
- Vieta E. Bipolar mixed states and their treatment. Expert Rev. Neurother.5(1), 63–68 (2005).
- Muñoz RA. Oxcarbamazepine for the treatment of bipolar disorder. Presented at: The 5th International Conference on Bipolar Disorder. Pittsburgh, USA, 12–14 June 2003.
- Benedetti A, Lattanzi L, Pini S, Musetti L, Dell’Osso L, Cassano GB. Oxcarbamazepine as add-on treatment in patients with bipolar, mixed or depressive episode. J. Affect. Disord.79(1–3), 273–277 (2004).
- Conway CR, Chibnall JT, Nelson LA et al. An open-label trial of adjunctive oxcarbazepine for bipolar disorder. J. Clin. Psychopharmacol.26(1), 95–97 (2006).
- Hummel B, Walden J, Stampfer R et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord.4, 412–417 (2002).
- Raja M, Azzoni A. Oxcarbazepine vs valproato in the treatment of mood and schizoaffective disorders. Int. J. Neuropsychopharmacol.6, 409–414 (2003).
- Centorrino F, Albert MJ, Berry JM et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord.5, 370–74 (2003).
- Benabarre A, Durán A, Bernardo M. Estudio abierto de la seguridad y la eficacia de oxcarbazepina como tratamiento coadyuvante para los trastornos esquizoafectivos. Psiquiatría Biológica11(Suppl. 1) 56, (2004).
- Comes M, Vieta E, Benabarre A, Goikolea JM, Corbella B, Colom F. Oxcarbazepine for hipomania in bipolar II disorder. Presented at: The 5th International Conference on Bipolar Disorder. PA, USA, 12–14 June 2003.
- Cabrera JF, Mühlbauer HD, Schley J, Stoll KD, Müller-Oerlinghausen B. Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry19, 282–283 (1986).
- Berv DA, Klugman J, Hsu DJ, Rosenquist KJ, Ghaemi SN. Prophylactic efficacy of oxcarbazepine in bipolar disorder. Presented at: The 5th International Conference on Bipolar Disorder. PA, USA, 12–14 June 2003.
- Deutschman DA, Deutschman DH, Chalakian JS. Oxcarbazepine efficacy/safety in bipolar disorder: a retrospective review of 249 patients. Presented at: The 5th International Conference on Bipolar Disorder. PA, USA, 12–14 June 2003.
- Vieta E, Comes M, García-Campayo J et al. A double-blind, placebo-controlled, randomized prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Presented at: The Fifth European Stanley Conference on Bipolar Disorder. Barcelona, Spain, 5–7 October 2006.
- Teitelbaum M. Oxcarbazepine in bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry40, 993–994 (2001).
- Nasr S. Oxcarbazepine for mood disorders. Am. J. Psychiatry159, 1793 (2002).
- Malek-Ahmadi P, Hanretta A. Possible reduction in posttraumatic stress disorder symptoms with oxcarbazepine in a patient with bipolar disorder. Ann. Pharmacother.38, 1852–1854 (2004).
- Ghaemi SN, Ko JY, Katzow JJ. Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review. Bipolar Disord.4, 70–74 (2002).
- Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ. Oxcarbazepine treatment of bipolar disorder. J. Clin. Psychiatry64(8), 43–45 (2003).
- Platt DE, Munasifi FA, McKay LM. Retrospective chart review on the use of oxcarbazepine in patients with bipolar disorder. Presented at: The 5th International Conference on Bipolar Disorder. PA, USA, June 12–14 2003.
- Pratoomsri W, Yatham LN, Sohn C-H, Solomons K, Lam RW. Oxcarbazepine add-on in the treatment of refractory bipolar disorder. Bipolar Disord.7(Suppl. 5), S37–S42 (2005).
- Schaffer CB, Schaffer LC, Howe JL. The use of oxcarbazepine in refractory bipolar outpatients. Presented at: The 5th International Conference on Bipolar Disorder. Pittsburgh, USA, June 12–14 (2003).
- Muzina DJ, El-Sayegh S, Calabrese JR. Antiepileptic drugs in psychiatry-focus on randomized controlled trial. Epilepsy Res.50, 195–202 (2002).
- Gajwani P, Forsthoff A, Muzina D et al. Antiepileptic drugs in mood-disordered patients. Epilepsia46(Suppl. 4), 38–44 (2005).
- Hellewell JS. Oxcarbamazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J. Affect. Disord.72(Suppl. 1), S23–S4 (2002).
- Beydoun A. Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disorders. Epilepsy Behav.3, S18–S22 (2002).
- Houtkooper MA, Lammertsma A, Meyer JW et al. Oxcarbazepine (GP 47 680): a possible alternative to carbamazepine? Epilepsia28, 693–698 (1987).
- Muscatello MR, Pacetti M, Cacciola M et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia46(5), 771–774 (2005).
- Pratoomsri W, Yatham LN, Bond DJ, Lam RW, Sohn C-H. Oxcarbamazepine in the treatment of bipolar disorder: a review. Can. J. Psychiatry5(8), 540–545 (2006).
- Wildgrube C. Case studies on prophylactic Long-term effects of oxcarbazepine in recurrent affective disorders. Int. Clin. Psychopharmacol.5, S89–S94 (1990).
- Macmillan CM, Korndorfer SR, Rao S, Fleisher CA, Mezzacappa E, Gonzalez-Heydrich J. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J. Psychiatr. Pract.12(4), 214–222 (2006).
- Velikonja M, Heinrich K. Effect of oxcarbazepine (GP 47 680) on affective and shizoaffective symptoms: a preliminary report. In: Anticonvulsants in Affective Disorders. Emrich HM, Okuma T, Mueller AA (Eds). Elsevier Science Publishers BV, Amsterdam, The Netherlands (1984).